Reintroduction after SAMS is challenging and may involve using alternate statins, intermittent dosing, correcting vitamin D deficiency, or transitioning to non-statin agents like ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Here, PCSK9 is linked to vitamin D deficiency.